Exact Sciences Corporation
EXAS
$46.35
$0.461.00%
| Weiss Ratings | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.07 | |||
| Price History | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.52% | |||
| 30-Day Total Return | -16.35% | |||
| 60-Day Total Return | -26.62% | |||
| 90-Day Total Return | -33.44% | |||
| Year to Date Total Return | -18.58% | |||
| 1-Year Total Return | -23.64% | |||
| 2-Year Total Return | -27.05% | |||
| 3-Year Total Return | -21.05% | |||
| 5-Year Total Return | -10.02% | |||
| 52-Week High % Change | -42.36% | |||
| 52-Week Low % Change | 12.96% | |||
| Price | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $79.62 | |||
| 52-Week Low Price | $40.62 | |||
| 52-Week Low Price (Date) | Jun 25, 2024 | |||
| 52-Week High Price (Date) | Apr 02, 2024 | |||
| Valuation | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 8.52B | |||
| Enterprise Value | 10.26B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.57 | |||
| Earnings Per Share Growth | 390.95% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.08 | |||
| Price/Book (Q) | 3.55 | |||
| Enterprise Value/Revenue (TTM) | 3.72 | |||
| Price | $46.35 | |||
| Enterprise Value/EBITDA (TTM) | 238.65 | |||
| Enterprise Value/EBIT | -59.71 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 185.31M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 608 284 5700 | |||
| Address | 5505 Endeavor Lane Madison, WI 53719 | |||
| Website | www.exactsciences.com | |||
| Country | United States | |||
| Year Founded | 1995 | |||
| Profitability | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -6.22% | |||
| Profit Margin | -37.29% | |||
| Management Effectiveness | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -1.73% | |||
| Return on Equity | -- | |||
| Income Statement | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.76B | |||
| Total Revenue (TTM) | 2.76B | |||
| Revenue Per Share | $14.89 | |||
| Gross Profit (TTM) | 1.92B | |||
| EBITDA (TTM) | 43.00M | |||
| EBIT (TTM) | -171.86M | |||
| Net Income (TTM) | -1.03B | |||
| Net Income Avl. to Common (TTM) | -1.03B | |||
| Total Revenue Growth (Q YOY) | 10.29% | |||
| Earnings Growth (Q YOY) | -1,637.30% | |||
| EPS Diluted (TTM) | -5.57 | |||
| EPS Diluted Growth (Q YOY) | -1,600.69% | |||
| Balance Sheet | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.04B | |||
| Cash Per Share (Q) | $5.60 | |||
| Total Current Assets (Q) | 1.57B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.40B | |||
| Current Ratio (Q) | 2.146 | |||
| Book Value Per Share (Q) | $12.94 | |||
| Total Assets (Q) | 5.93B | |||
| Total Current Liabilities (Q) | 732.19M | |||
| Total Debt (Q) | 2.78B | |||
| Total Liabilities (Q) | 3.53B | |||
| Total Common Equity (Q) | 2.40B | |||
| Cash Flow | EXAS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -442.16M | |||
| Cash from Financing (TTM) | 231.87M | |||
| Net Change in Cash (TTM) | -3.04M | |||
| Levered Free Cash Flow (TTM) | 63.38M | |||
| Cash from Operations (TTM) | 210.54M | |||
